LAB Q1 2022 Earnings — Standard BioTools Inc. Revenue & Financial Results | Market Cap Arena

LABStandard BioTools Inc.

$388M

Q1 2022 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$27M-19.2% YoY

Gross Profit

$12M46.2% margin

Operating Income

-$28M-103.8% margin

Net Income

-$76M-287.8% margin

EPS (Diluted)

$-0.99

QoQ Revenue Growth

-30.7%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$272M

Total Liabilities

$250M

Stockholders' Equity

$22M

Cash & Equivalents

$30M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$27M	$33M	-19.2%
Gross Profit	$12M	$19M	-35.7%
Operating Income	-$28M	-$19M	-42.4%
Net Income	-$76M	-$19M	-305.3%

Revenue Segments

Product

$20M43%

Consumables

$12M27%

Instruments

$8M16%

Service

$6M13%

License

$268,0001%

Product and Service, Other

$268,0001%

Collaboration Revenue

$88,0000%

Geographic Segments

Americas

$13M49%

EMEA

$9M32%

Asia Pacific

$5M19%